Literature DB >> 7923674

Superiority of treadmill walking exercise versus strength training for patients with peripheral arterial disease. Implications for the mechanism of the training response.

W R Hiatt1, E E Wolfel, R H Meier, J G Regensteiner.   

Abstract

BACKGROUND: In patients with intermittent claudication, a supervised walking exercise program increases peak exercise performance and community-based functional status. Patients with peripheral arterial disease also have muscle weakness in the affected extremity that may contribute to the walking impairment. However, the potential benefits of training modalities other than walking exercise, such as strength training, have not been critically evaluated in this patient population. The present study tested the hypothesis that a strength training program would be as effective as treadmill walking exercise and that combinations of strengthening and walking exercise would be more effective than either alone in improving exercise performance. METHODS AND
RESULTS: Twenty-nine patients with disabling claudication were randomized to 12 weeks of supervised walking exercise on a treadmill (3 h/wk at a work intensity sufficient to produce claudication), strength training (3 h/wk of resistive training of five muscle groups of each leg), or a nonexercising control group. Graded treadmill testing was performed to maximally tolerated claudication pain to define changes in peak exercise performance. After 12 weeks, patients in the treadmill training program had a 74 +/- 58% increase in peak walking time as well as improvements in peak oxygen consumption (VO2) and the onset of claudication pain. Patients in the strength-trained group had a 36 +/- 48% increase in peak walking time but no change in peak VO2 or claudication onset time. Control subjects had no changes in any of these measures over the 12-week period. After the first 12 weeks, patients in the initial walking exercise group continued for 12 more weeks of supervised treadmill training. This resulted in an additional 49 +/- 53% increase in peak walking time (total of 128 +/- 99% increase over the 24 weeks). After the initial 12 weeks, patients in the strength-trained group began 12 weeks of supervised treadmill training, and patients in the control group participated in a 12-week combined program of strengthening and treadmill walking exercise. The combined strength and treadmill training program and treadmill training after 12 weeks of strength training resulted in increases in peak exercise performance similar to those observed with 12 weeks of treadmill training alone.
CONCLUSIONS: A supervised treadmill walking exercise program is an effective means to improve exercise performance in patients with intermittent claudication, with continued improvement over 24 weeks of training. In contrast, 12 weeks of strength training was less effective than 12 weeks of supervised treadmill walking exercise. Finally, strength training, whether sequential or concomitant, did not augment the response to a walking exercise program.

Entities:  

Mesh:

Year:  1994        PMID: 7923674     DOI: 10.1161/01.cir.90.4.1866

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  60 in total

1.  Plantar flexion training primes peripheral arterial disease patients for improvements in cardiac function.

Authors:  Jan Helgerud; Eivind Wang; Mats Peder Mosti; Øystein Nordrum Wiggen; Jan Hoff
Journal:  Eur J Appl Physiol       Date:  2009-02-24       Impact factor: 3.078

2.  Plantar flexion: an effective training for peripheral arterial disease.

Authors:  Eivind Wang; Jan Hoff; Henrik Loe; Nils Kaehler; Jan Helgerud
Journal:  Eur J Appl Physiol       Date:  2008-08-23       Impact factor: 3.078

3.  Supervised exercise for intermittent claudication - an under-utilised tool.

Authors:  Joseph Shalhoub; Maher Hamish; Alun H Davies
Journal:  Ann R Coll Surg Engl       Date:  2009-06-25       Impact factor: 1.891

4.  Physical activity and lower limb lymphedema among uterine cancer survivors.

Authors:  Justin C Brown; Gabriella M John; Saya Segal; Christina S Chu; Kathryn H Schmitz
Journal:  Med Sci Sports Exerc       Date:  2013-11       Impact factor: 5.411

5.  Exercise therapy for claudication: latest advances.

Authors:  Ryan J Mays; Judith G Regensteiner
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-04

Review 6.  Optimising exercise training in peripheral arterial disease.

Authors:  Andrew C Bulmer; Jeff S Coombes
Journal:  Sports Med       Date:  2004       Impact factor: 11.136

7.  Treadmill exercise and resistance training in patients with peripheral arterial disease with and without intermittent claudication: a randomized controlled trial.

Authors:  Mary M McDermott; Philip Ades; Jack M Guralnik; Alan Dyer; Luigi Ferrucci; Kiang Liu; Miriam Nelson; Donald Lloyd-Jones; Linda Van Horn; Daniel Garside; Melina Kibbe; Kathryn Domanchuk; James H Stein; Yihua Liao; Huimin Tao; David Green; William H Pearce; Joseph R Schneider; David McPherson; Susan T Laing; Walter J McCarthy; Adhir Shroff; Michael H Criqui
Journal:  JAMA       Date:  2009-01-14       Impact factor: 56.272

Review 8.  The effect of exercise on fitness and performance-based tests of function in intermittent claudication: a systematic review.

Authors:  Belinda J Parmenter; Jacqueline Raymond; Maria A Fiatarone Singh
Journal:  Sports Med       Date:  2013-06       Impact factor: 11.136

9.  Autologous peripheral blood CD133+ cell implantation for limb salvage in patients with critical limb ischemia.

Authors:  R K Burt; A Testori; Y Oyama; H E Rodriguez; K Yaung; M Villa; J M Bucha; F Milanetti; J Sheehan; N Rajamannan; W H Pearce
Journal:  Bone Marrow Transplant       Date:  2009-05-18       Impact factor: 5.483

10.  Associations between lower extremity ischemia, upper and lower extremity strength, and functional impairment with peripheral arterial disease.

Authors:  Mary M McDermott; Lu Tian; Luigi Ferrucci; Kiang Liu; Jack M Guralnik; Yihua Liao; William H Pearce; Michael H Criqui
Journal:  J Am Geriatr Soc       Date:  2008-02-13       Impact factor: 5.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.